Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TVRD Tvardi Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: TVRD
Price (delayed)
$25.23
Market cap
$236.18M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$30.01
Enterprise value
$247.78M
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in
Highlights
The quick ratio has surged by 185% since the previous quarter
TVRD's net income has soared by 63% YoY and by 36% QoQ
The revenue has dropped by 55% year-on-year but it is up by 6% since the previous quarter
TVRD's gross profit is down by 41% YoY but it is up by 16% from the previous quarter
Tvardi Therapeutics's equity has plunged by 127% YoY and by 76% from the previous quarter
TVRD's debt is up by 3.1% since the previous quarter
Key stats
What are the main financial stats of TVRD
Market
Valuations
Earnings
Shares outstanding
9.36M
Market cap
$236.18M
Enterprise value
$247.78M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
5.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.73
Revenue
$7.57M
Gross profit
$7.57M
Operating income
-$38.34M
Net income
-$45.08M
EBIT
-$36.12M
EBITDA
-$35.47M
Free cash flow
-$35.37M
Per share
Balance sheet
Liquidity
EPS
-$30.01
EPS diluted
-$30.01
Free cash flow per share
-$23.2
Book value per share
-$5.3
Revenue per share
$4.97
TBVPS
$25.55
Total assets
$38.95M
Total liabilities
$47.02M
Debt
$45.82M
Equity
-$8.07M
Working capital
$37.75M
Debt to equity
-5.68
Current ratio
32.48
Quick ratio
30.4
Net debt/EBITDA
-0.33
Margins
Efficiency
Dividend
EBITDA margin
-468.5%
Gross margin
100%
Net margin
-595.4%
Operating margin
-506.4%
Return on assets
-87.3%
Return on equity
N/A
Return on invested capital
-72.6%
Return on capital employed
-95.7%
Return on sales
-477%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TVRD stock price
How has the Tvardi Therapeutics stock price performed over time
Intraday
-5.79%
1 week
-1.48%
1 month
38.26%
1 year
-12.97%
YTD
37.42%
QTD
65.88%
Financial performance
How have Tvardi Therapeutics's revenue and profit performed over time
Revenue
$7.57M
Gross profit
$7.57M
Operating income
-$38.34M
Net income
-$45.08M
Gross margin
100%
Net margin
-595.4%
Tvardi Therapeutics's operating income has soared by 69% YoY and by 42% from the previous quarter
TVRD's net income has soared by 63% YoY and by 36% QoQ
The revenue has dropped by 55% year-on-year but it is up by 6% since the previous quarter
Tvardi Therapeutics's operating margin has increased by 45% from the previous quarter and by 31% YoY
Price vs fundamentals
How does TVRD's price correlate with its fundamentals
Growth
What is Tvardi Therapeutics's growth rate over time
Valuation
What is Tvardi Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
5.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.73
Tvardi Therapeutics's EPS has soared by 63% YoY and by 36% from the previous quarter
Tvardi Therapeutics's equity has plunged by 127% YoY and by 76% from the previous quarter
TVRD's P/S is 103% above its last 4 quarters average of 2.5 but 49% below its 5-year quarterly average of 10.0
The revenue has dropped by 55% year-on-year but it is up by 6% since the previous quarter
Efficiency
How efficient is Tvardi Therapeutics business performance
TVRD's return on invested capital has surged by 62% year-on-year and by 36% since the previous quarter
Tvardi Therapeutics's ROS has increased by 46% from the previous quarter and by 33% YoY
TVRD's ROA is up by 21% QoQ and by 17% YoY
Dividends
What is TVRD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TVRD.
Financial health
How did Tvardi Therapeutics financials performed over time
The total assets is 17% less than the total liabilities
Tvardi Therapeutics's current ratio has soared by 194% from the previous quarter
The quick ratio has surged by 185% since the previous quarter
Tvardi Therapeutics's equity has plunged by 127% YoY and by 76% from the previous quarter
The company's debt to equity rose by 41% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.